

# Evandro de Azambuja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2155806/publications.pdf>

Version: 2024-02-01

210  
papers

17,878  
citations

22099

59  
h-index

14156

128  
g-index

213  
all docs

213  
docs citations

213  
times ranked

20848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013, 31, 860-867.	0.8	1,342
2	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2012, 379, 633-640.	6.3	1,165
3	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	13.9	1,033
4	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	2.9	920
5	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , 2017, 389, 1195-1205.	6.3	770
6	Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
7	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
8	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet, The</i> , 2013, 382, 1021-1028.	6.3	447
9	Planning cancer control in Latin America and the Caribbean. <i>Lancet Oncology, The</i> , 2013, 14, 391-436.	5.1	394
10	Dissecting the Heterogeneity of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1879-1887.	0.8	388
11	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology, The</i> , 2014, 15, 1137-1146.	5.1	382
12	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	2.9	350
13	An update on PARP inhibitors—moving to the adjuvant setting. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 27-41.	12.5	316
14	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1034-1042.	0.8	315
15	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
16	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2014, 32, 2794-2803.	0.8	298
17	Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. <i>Oncologist</i> , 2007, 12, 1443-1455.	1.9	297
18	Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , 2020, 139, 43-50.	1.3	267

#	ARTICLE	IF	CITATIONS
19	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3422-3428.	0.8	228
20	Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 73-79.	0.8	215
21	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , 2014, 32, 2159-2165.	0.8	207
22	<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1334-1339.	0.8	201
23	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). <i>Lancet Oncology</i> , 2013, 14, 244-248.	5.1	172
24	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
25	Multifactorial Approach to Predicting Resistance to Anthracyclines. <i>Journal of Clinical Oncology</i> , 2011, 29, 1578-1586.	0.8	169
26	Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 2962-2969.	0.8	164
27	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. <i>Journal of the National Cancer Institute</i> , 2018, 110, 426-429.	3.0	143
28	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 145-153.	1.1	137
29	<sup>18</sup> F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1862-1868.	2.8	132
30	Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation. <i>Head and Neck</i> , 2006, 28, 256-269.	0.9	125
31	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
32	HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. <i>Cancers</i> , 2021, 13, 2824.	1.7	117
33	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	0.8	116
34	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 13-22.	1.1	114
35	Role of Troponins I and T and <i>N</i> -Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. <i>Journal of Clinical Oncology</i> , 2017, 35, 878-884.	0.8	113
36	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. <i>ESMO Open</i> , 2020, 5, e000793.	2.0	113

#	ARTICLE	IF	CITATIONS
37	Improving quality of life after breast cancer: Dealing with symptoms. <i>Maturitas</i> , 2011, 70, 343-348.	1.0	105
38	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors $\leq$ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2600-2608.	0.8	91
39	Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. <i>Targeted Oncology</i> , 2009, 4, 77-88.	1.7	90
40	Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013, 22, 606-615.	0.9	87
41	Achievements in Systemic Therapies in the Pergenomic Era in Metastatic Breast Cancer. <i>Oncologist</i> , 2007, 12, 253-270.	1.9	85
42	Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies. <i>Breast</i> , 2013, 22, S152-S155.	0.9	84
43	The Exciting New Field of HER2-Low Breast Cancer Treatment. <i>Cancers</i> , 2021, 13, 1015.	1.7	83
44	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. <i>Clinical Cancer Research</i> , 2017, 23, 2702-2712.	3.2	82
45	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. <i>Journal of Oncology</i> , 2012, 2012, 1-8.	0.6	79
46	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
47	Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the <i>œdo ut des</i> ) Tj ETQq1 1 0.784314 rgBT /Over	2.0	76
48	Twenty years of anti-HER2 therapy-associated cardiotoxicity. <i>ESMO Open</i> , 2016, 1, e000073.	2.0	76
49	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1226-1238.	5.1	76
50	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	3.4	75
51	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. <i>JAMA Oncology</i> , 2016, 2, 1040.	3.4	73
52	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	3.0	73
53	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
54	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	0.8	72

#	ARTICLE	IF	CITATIONS
55	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. <i>Clinical Cancer Research</i> , 2015, 21, 569-576.	3.2	71
56	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
57	HER2-positive advanced breast cancer treatment in 2020. <i>Cancer Treatment Reviews</i> , 2020, 88, 102033.	3.4	70
58	The 17q12-q21 amplicon: Her2 and topoisomerase-III± and their importance to the biology of solid tumours. <i>Cancer Treatment Reviews</i> , 2007, 33, 64-77.	3.4	69
59	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x27-x42.	0.6	63
60	Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. <i>ESMO Open</i> , 2020, 5, e000947.	2.0	63
61	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61
62	Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). <i>Breast Cancer Research and Treatment</i> , 2012, 133, 387-391.	1.1	61
63	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	0.8	60
64	HER2-positive breast cancer is lost in translation: time for patient-centered research. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 669-681.	12.5	59
65	How I treat metastatic triple-negative breast cancer. <i>ESMO Open</i> , 2019, 4, e000504.	2.0	59
66	Breast cancer treatment-induced cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1021-1038.	1.0	58
67	Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2020, 126, 65-73.	1.3	58
68	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2± positive early breast cancer: Analysis from the NeoALTO (BIG 1±06) and ALTO (BIG) Tj ETQq00 0 rgB57Overlock	0.0	57
69	Larotaxel: broadening the road with new taxanes. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1183-1189.	1.9	56
70	Menopausal hormone therapy use in 17 European countries during the last decade. <i>Maturitas</i> , 2014, 79, 287-291.	1.0	55
71	Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2009, 9, 148-162.	0.8	53
72	Beyond trastuzumab: New treatment options for HER2-positive breast cancer. <i>Breast</i> , 2011, 20, S20-S27.	0.9	53

#	ARTICLE	IF	CITATIONS
73	Breast Cancer: Achievements in Adjuvant Systemic Therapies in the Pre-Genomic Era. <i>Oncologist</i> , 2006, 11, 111-125.	1.9	52
74	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012, 14, R70.	2.2	52
75	Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	1.3	51
76	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 316-324.	0.4	50
77	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
78	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	1.1	49
79	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	2.0	49
80	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	2.0	48
81	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	2.9	45
82	Jumping higher: is it still possible? The ALTTO trial challenge. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1883-1890.	1.1	43
83	Molecular Profiling of a Tumor of Unknown Origin. <i>New England Journal of Medicine</i> , 2006, 355, 1071-1072.	13.9	42
84	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3887-3895.	3.2	42
85	Motherhood after breast cancer: searching for la dolce vita. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 287-298.	1.1	41
86	Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. <i>European Journal of Cancer</i> , 2015, 51, 2517-2524.	1.3	40
87	Adjuvant trastuzumab: a 10-year overview of its benefit. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 61-74.	1.1	40
88	Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 27-37.	1.1	40
89	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	0.8	39
90	A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 161-171.	1.1	39

#	ARTICLE	IF	CITATIONS
91	Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 110-121.	2.0	38
92	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
93	HER-2 as a Target for Breast Cancer Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1848-1852.	3.2	36
94	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , 2017, 87, 10-20.	1.3	35
95	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	2.0	35
96	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTO (BIG 2-06) randomized clinical trial. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 103-114.	1.1	34
97	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	0.9	33
98	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	1.8	33
99	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
100	Molecular targeted therapies in breast cancer: Where are we now?. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1375-1387.	1.2	32
101	Final 10-year results of the Breast International Group 2008 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
102	First results from the phase III ALTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T+L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA4-LBA4.	0.8	32
103	Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 629-649.	1.1	31
104	Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?. <i>ESMO Open</i> , 2020, 5, e001112.	2.0	30
105	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 57.	1.8	30
106	HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 488-496.	0.9	30
107	Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. <i>Oncologist</i> , 2013, 18, 134-140.	1.9	29
108	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 567-591.	1.9	29

#	ARTICLE	IF	CITATIONS
109	Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. ESMO Open, 2018, 3, e000440.	2.0	27
110	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. PLoS ONE, 2016, 11, e0154009.	1.1	27
111	Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis. Frontiers in Oncology, 2018, 8, 156.	1.3	26
112	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opinion on Biological Therapy, 2021, 21, 945-962.	1.4	26
113	Targeted therapies in breast cancer: are heart and vessels also being targeted?. Breast Cancer Research, 2012, 14, 209.	2.2	24
114	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. Journal of the National Cancer Institute, 2016, 108, djw037.	3.0	24
115	Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study. Journal of Clinical Oncology, 2009, 27, 720-725.	0.8	23
116	Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. Lancet Oncology, The, 2011, 12, 209-211.	5.1	22
117	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer, 2020, 122, 1453-1460.	2.9	22
118	ecancermedalscience. Ecancermedalscience, 2014, 8, 425.	0.6	19
119	Current perspectives of epothilones in breast cancer. European Journal of Cancer, 2008, 44, 341-352.	1.3	18
120	Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology, 2008, 5, 645-654.	4.3	18
121	HER2-overexpressing breast cancer. Current Opinion in Oncology, 2011, 23, 547-558.	1.1	18
122	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 4.	1.3	17
123	Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean. Lancet Oncology, The, 2021, 22, e488-e500.	5.1	17
124	Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. Maturitas, 2016, 84, 81-88.	1.0	16
125	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 62, 123-132.	3.4	16
126	Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. ESMO Open, 2020, 5, e000842.	2.0	16



#	ARTICLE	IF	CITATIONS
127	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
128	Emerging issues related to COVID-19 vaccination in patients with cancer. <i>Oncology and Therapy</i> , 2021, 1-11.	1.0	15
129	Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2018, 39, 14-18.	0.9	14
130	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 135-144.	2.0	14
131	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.	1.1	14
132	Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 262-273.e7.	1.1	14
133	CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13535.	1.7	14
134	An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case. <i>European Journal of Cancer</i> , 2014, 50, 3089-3097.	1.3	13
135	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
136	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	3.4	13
137	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019, 24, e1034-e1043.	1.9	13
138	Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 467-470.	3.0	13
139	Dual human epidermal growth factor receptor 2 blockade. <i>Current Opinion in Oncology</i> , 2012, 24, 612-622.	1.1	12
140	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	2.3	12
141	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	1.3	12
142	Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100501.	2.0	12
143	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. <i>Breast</i> , 2014, 23, 473-481.	0.9	11
144	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	2.0	11

#	ARTICLE	IF	CITATIONS
145	I-SPY 2: optimising cancer drug development in the 21st century. <i>ESMO Open</i> , 2016, 1, e000113.	2.0	11
146	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3363-3372.	1.0	11
147	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	1.3	11
148	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
149	Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?. <i>ESMO Open</i> , 2018, 3, e000324.	2.0	10
150	Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 607-615.	1.1	10
151	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 183-192.	0.9	10
152	Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA. <i>PLoS ONE</i> , 2017, 12, e0172351.	1.1	10
153	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. <i>Breast Cancer Research</i> , 2009, 11, 201.	2.2	9
154	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , 2018, 52, 424-432.	1.4	9
155	Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388.	0.5	9
156	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	2.0	9
157	Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?. <i>ESMO Open</i> , 2018, 3, e000350.	2.0	8
158	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 67.	2.3	8
159	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	3.2	8
160	Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 512-512.	0.8	8
161	Novel therapeutics in breast cancer—Looking to the future. <i>Update on Cancer Therapeutics</i> , 2009, 3, 189-205.	0.9	7
162	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	1.1	7

#	ARTICLE	IF	CITATIONS
163	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). <i>Acta Oncológica</i> , 2020, 59, 723-725.	0.8	7
164	Trastuzumab (Herceptin) for Early-Stage Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 239-256.	0.9	6
165	Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge. <i>Journal of Clinical Oncology</i> , 2010, 28, e353-e354.	0.8	6
166	Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. <i>ESMO Open</i> , 2020, 5, e000659.	2.0	6
167	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021, 7, 455-463.	0.8	6
168	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6
169	Oncofertility counselling in premenopausal women with HER2-positive breast cancer. <i>Oncotarget</i> , 2019, 10, 926-929.	0.8	6
170	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	1.9	6
171	Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy. <i>Annals of Nuclear Medicine</i> , 2005, 19, 131-135.	1.2	5
172	Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP). <i>Journal of Chemotherapy</i> , 2013, 25, 239-246.	0.7	5
173	Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 43-51.	1.1	5
174	CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?. <i>ESMO Open</i> , 2020, 5, e001132.	2.0	5
175	Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102940.	2.0	5
176	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5607-5618.	3.2	5
177	Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 13209-13220.	0.8	5
178	Shrinking the Tumor, Shrinking the Patient Sample Size: The Early Disclosure Dilemma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6803-6804.	0.8	4
179	Long-term survival in pituitary metastasis from breast cancer. <i>Breast</i> , 2006, 15, 445-446.	0.9	4
180	OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy. <i>Journal of Clinical Oncology</i> , 2006, 24, 5176-5177.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Clinical practice-changing trials: the HERA study paradigm. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1249-1256.	1.1	4
182	ER+/HER2+ breast cancer: are we really de-escalating?. <i>Annals of Oncology</i> , 2019, 30, 875-877.	0.6	4
183	Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 457-462.	1.1	4
184	Phosphoethanolamine and the danger of unproven drugs. <i>Ecancermedicalsecience</i> , 2016, 10, 681.	0.6	3
185	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	3.0	3
186	Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 116-119.	0.9	2
187	Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer. <i>Onkologie</i> , 2012, 35, 476-478.	1.1	2
188	Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond. <i>Breast Cancer Management</i> , 2012, 1, 217-233.	0.2	2
189	How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer. <i>Breast Care</i> , 2013, 8, 264-269.	0.8	2
190	Denosumab in early-stage breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, e234-e235.	5.1	2
191	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020, 5, e000979.	2.0	2
192	Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 563-573.	1.1	2
193	Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial. <i>European Journal of Cancer</i> , 2021, 144, 351-359.	1.3	2
194	Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10066-10066.	0.8	2
195	An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10068-10068.	0.8	2
196	Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients. <i>Chinese Clinical Oncology</i> , 2018, 7, 4-4.	0.4	2
197	Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002656.	0.8	2
198	Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 308-318.	1.1	2

#	ARTICLE	IF	CITATIONS
199	End-of-Life Care: The Red Alert for Physicians. <i>Oncologist</i> , 2006, 11, 851-852.	1.9	1
200	Reply to C. Fontanella et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3459-3459.	0.8	1
201	Threat posed by unproven drugs in medical oncology. <i>ESMO Open</i> , 2016, 1, e000064.	2.0	1
202	Male breast cancer: finding the way in this uncommon path. <i>ESMO Open</i> , 2017, 2, e000169.	2.0	1
203	Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1205-1215.	1.5	1
204	PERSEPHONE – implications for clinical practice in 2019. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 663-664.	12.5	1
205	Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer – Authors' reply. <i>Lancet</i> , The, 2012, 379, 2238.	6.3	0
206	In Reply to Belkacemi and Tsoutsou. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 467-468.	0.4	0
207	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , 2019, 39, 797-802.	0.5	0
208	Are We RESPECTing Older Patients With Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3727-3730.	0.8	0
209	Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. <i>ESMO Open</i> , 2020, 5, e000688.	2.0	0
210	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. <i>Cancer Research</i> , 2022, 82, PD5-06-PD5-06.	0.4	0